RT Journal Article
SR Electronic
T1 Increased Serum Interleukin 22 in Patients with Rheumatoid Arthritis and Correlation with Disease Activity
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1320
OP 1325
DO 10.3899/jrheum.111027
VO 39
IS 7
A1 da ROCHA, LAURINDO FERREIRA
A1 DUARTE, ÂNGELA LUZIA BRANCO PINTO
A1 DANTAS, ANDRÉA TAVARES
A1 MARIZ, HENRIQUE ATAÍDE
A1 PITTA, IVAN da ROCHA
A1 GALDINO, SUELY LINS
A1 PITTA, MAIRA GALDINO da ROCHA
YR 2012
UL http://www.jrheum.org/content/39/7/1320.abstract
AB Objective. To analyze the role of interleukin 22 (IL-22) in rheumatoid arthritis (RA). Methods. IL-22 serum levels were measured in 83 patients with established RA under treatment with disease-modifying antirheumatic drugs and in 30 healthy controls matched for age and sex. Patients were assessed for clinical and laboratory variables. Correlations of IL-22 serum levels with disease activity measures [Clinical Disease Activity Index (CDAI) and Disease Activity Score for 28 joints (DAS28)], serological markers, bone erosions, and demographic factors were assessed. Peripheral blood mononuclear cells (PBMC) from 30 patients with RA and 14 controls were purified and stimulated in vitro with phorbol myristate acetate (PMA)/ionomycin. IL-22 production by PBMC and in serum was investigated by ELISA. Results. IL-22 levels were increased in patients with RA compared with controls (mean 432.37 pg/ml and 67.45 pg/ml, respectively; p < 0.001). Levels of IL-22 correlated with DAS28 and CDAI measures. Rheumatoid factor (RF) positivity was correlated with higher levels of IL-22 in patients with RA (mean 575.08 pg/ml; p = 0.001). The presence of bone erosions was associated with high IL-22 levels (p = 0.0001). PBMC stimulated with PMA/ionomycin expressed higher levels of IL-22 in patients with RA than controls but this was not significant (mean 584.75 pg/ml and 295.57 pg/ml; p = 0.553). Conclusion. IL-22 is elevated in the serum of patients with established RA. Elevated serum IL-22 allows discrimination between patients with different clinical and laboratory measures and indicates the potential of IL-22 as an additional tool for assessment of activity in RA, particularly in patients with RF antibodies and longterm disease. IL-22 is associated with bone-destructive disease.